Signaling function of Na,K-ATPase induced by ouabain against LPS as an inflammation model in hippocampus

Journal of Neuroinflammation

Volumn 11, Issue 1, 2014, Pages

  Kinoshita, Paula Fernanda ^a   Yshii, Lidia Mitiko ^a   Vasconcelos, Andrea Rodrigues ^a   Orellana, Ana Maria Marques ^a   Lima, Larissa de Sá ^a   Davel, Ana Paula Couto ^a   Rossoni, Luciana Venturini ^a   Kawamoto, Elisa Mitiko ^a   Scavone, Cristoforo ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Inflammation; LPS; Na,K ATPase; NF B; Ouabain; TNF

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); BRAIN DERIVED NEUROTROPHIC FACTOR; CORTICOSTERONE; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; GLIAL FIBRILLARY ACIDIC PROTEIN; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; MESSENGER RNA; OUABAIN; PROTEIN BAX; PROTEIN BCL 2; SODIUM CHLORIDE; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; ENZYME INHIBITOR; LIPOPOLYSACCHARIDE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL NUCLEUS; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; CYTOSOL; DENTATE GYRUS; ENCEPHALITIS; ENZYME ACTIVITY; HIPPOCAMPUS; LOW DRUG DOSE; MALE; NEUROPROTECTION; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN TRANSPORT; RAT; SIGNAL TRANSDUCTION; ANIMAL; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; IMMUNOLOGY; INFLAMMATION; WISTAR RAT;

ANIMALS; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; HIPPOCAMPUS; INFLAMMATION; LIPOPOLYSACCHARIDES; MALE; OUABAIN; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; SODIUM-POTASSIUM-EXCHANGING ATPASE;

EID: 84924865332     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/s12974-014-0218-z     Document Type: Article

References (66)

1. Schoner W: Ouabain, a new steroid hormone of adrenal gland and hypothalamus. Exp Clin Endocrinol Diabetes 2000, 108:449-454.
2. Kawamura A, Guo J, Itagaki Y, Bell C, Wang Y, Haupert GT Jr, Magil S, Gallagher RT, Berova N, Nakanishi K: On the structure of endogenous ouabain. Proc Natl Acad Sci U S A 1999, 96:6654-6659.
3. Albers RW: Cell Membrane Structures and Functions. 6th edition. New York: Raven Press; 1999.
4. Fambrough DM: The sodium pump becomes a family. Trends Neurosci 1988, 11:325-328.
5. Levenson R: Isoforms of the Na, K-ATPase: family members in search of function. Rev Physiol Biochem Pharmacol 1994, 123:1-45.
6. Lingrel JB, Kuntzweiler T: Na+, K(+)-ATPase. J Biol Chem 1994, 269:19659-19662.
7. + -ATPase. Biochim Biophys Acta 1989, 988:185-220.
8. + -ATPase. Soc Gen Physiol Ser 1991, 46:63-76.
9. Minor N, Sha Q, Nichols C, Mercer R: The gamma subunit of the Na, K-ATPase induces cation channel activity. Proc Natl Acad Sci U S A 1998, 95:6521-6525.
10. Beltowski J, Wójcicka G: Regulation of renal tubular sodium transport by cardiac natriuretic peptides: two decades of research. Med Sci Monit 2002, 8:RA39-RA52.
11. Peng L, Arystarkhova E, Sweadner KJ: Plasticity of Na, K-ATPase isoform expression in cultures of flat astrocytes: species differences in gene expression. Glia 1998, 24:257-271.
12. De Fusco M, Marconi R, Silvestri L, Atorino L, Rampoldi L, Morgante L, Ballabio A, Aridon P, Casari G: Haploinsufficiency of ATP1A2 encoding the Na+/K+ pump alpha2 subunit associated with familial hemiplegic migraine type 2. Nat Genet 2003, 33:192-196.
13. Moseley AE, Williams MT, Schaefer TL, Bohanan CS, Neumann JC, Behbehani MM, Vorhees CV, Lingrel JB: Deficiency in Na, K-ATPase alpha isoform genes alters spatial learning, motor activity, and anxiety in mice. J Neurosci 2007, 27:616-626.
14. Heinzen EL, Swoboda KJ, Hitomi Y, Gurrieri F, Nicole S, de Vries B, Tiziano FD, Fontaine B, Walley NM, Heavin S, Panagiotakaki E, European Alternating Hemiplegia of Childhood (AHC) Genetics Consortium, Biobanca e Registro Clinico per l'Emiplegia Alternante (I.B.AHC) Consortium, European Network for Research on Alternating Hemiplegia (ENRAH) for Small and Medium-sized Enterpriese (SMEs) Consortium, Fiori S, Abiusi E, Di Pietro L, Sweney MT, Newcomb TM, Viollet L, Huff C, Jorde LB, Reyna SP, Murphy KJ, Shianna KV, Gumbs CE, Little L, Silver K, Ptáček LJ, Haan J, et al: De novo mutations in ATP1A3 cause alternating hemiplegia of childhood. Nat Genet 2012, 44:1030-1034.
15. Demos MK, van Karnebeek CD, Ross CJ, Adam S, Shen Y, Zhan SH, Shyr C, Horvath G, Suri M, Fryer A, Jones SJ, Friedman JM, FORGE Canada Consortium: A novel recurrent mutation in ATP1A3 causes CAPOS syndrome. Orphanet J Rare Dis 2014, 9:15. doi:10.1186/1750-1172-9-15.
16. Goldstein I, Lerer E, Laiba E, Mallet J, Mujaheed M, Laurent C, Rosen H, Ebstein RP, Lichtstein D: Association between sodium- and potassium-activated adenosine triphosphatase alpha isoforms and bipolar disorders. Biol Psychiatry 2009, 65:985-991.
17. Zhang LN, Sun YJ, Pan S, Li JX, Qu YE, Li Y, Wang YL, Gao ZB: Na(+)-K(+)-ATPase, a potent neuroprotective modulator against Alzheimer disease. Fundam Clin Pharmacol 2013, 27:96-103.
18. Aizman O, Aperia A: Na, K-ATPase as a signal transducer. Ann N Y Acad Sci 2003, 986:489-496.
19. Haas M, Wang H, Tian J, Xie Z: Src-mediated inter-receptor cross-talk between the Na+/K + -ATPase and the epidermal growth factor receptor relays the signal from ouabain to mitogen-activated protein kinases. J Biol Chem 2002, 277:18694-18702.
20. Murrell JR, Randall JD, Rosoff J, Zhao JL, Jensen RV, Gullans SR, Haupert GT Jr: Endogenous ouabain: upregulation of steroidogenic genes in hypertensive hypothalamus but not adrenal. Circulation 2005, 112:1301-1308.
21. El-Masri MA, Clark BJ, Qazzaz HM, Valdes R Jr: Human adrenal cells in culture produce both ouabain-like and dihydroouabain-like factors. Clin Chem 2002, 48:1720-1730.
22. Liu X, Spicarova Z, Rydholm S, Li J, Brismar H, Aperia A: Ankyrin B modulates the function of Na, K-ATPase/inositol 1,4,5-trisphosphate receptor signaling microdomain. J Biol Chem 2008, 283:11461-11468.
23. Liu XL, Miyakawa A, Aperia A, Krieger P: Na, K-ATPase generates calcium oscillations in hippocampal astrocytes. Neuroreport 2007, 18:597-600.
24. Xie Z, Askari A: Na(+)/K(+)-ATPase as a signal transducer. Eur J Biochem 2002, 269:2434-2439.
25. Xiao AY, Wei L, Xia S, Rothman S, Yu SP: Ionic mechanism of ouabain-induced concurrent apoptosis and necrosis in individual cultured cortical neurons. J Neurosci 2002, 22:1350-1362.
26. Golden WC, Martin LJ: Low-dose ouabain protects against excitotoxic apoptosis and up-regulates nuclear BLC-2 in vivo Neuroscience 2006, 37:133-144.
27. Burlaka I, Liu XL, Rebetz J, Arvidsson I, Yang L, Brismar H, Karpman D, Aperia A: Ouabain protects against Shiga toxin-triggered apoptosis by reversing the imbalance between Bax and Bcl-xL. J Am Soc Nephrol 2013, 24:1413-1423.
28. Sen R, Baltimore D: Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 1986, 46:705-716.
29. Ghosh S, May MJ, Kopp EB: NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998, 16:225-260.
30. Baeuerle PA, Baltimore D: NF-kappa B: ten years after. Cell 1996, 87:13-20.
31. Zandi E, Rothwarf DM, Delhase M, Hayakawa M, Karin M: The IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, necessary for IkappaB phosphorylation and NF-kappaB activation. Cell 1997, 91:243-252.
32. Mattson MP: Glutamate and neurotrophic factors in neuronal plasticity and disease. Ann N Y Acad Sci 2008, 1144:97-112.
33. Camandola S, Mattson MP: NF-kappa B as a therapeutic target in neurodegenerative diseases. Expert Opin Ther Targets 2007, 11:123-132.
34. Glaros TG, Chang S, Gilliam EA, Maitra U, Deng H, Li L: Causes and consequences of low grade endotoxemia and inflammatory diseases. Front Biosci (Schol Ed) 2013, 5:754-765.
35. Kawamoto EM, Scavone C, Mattson MP, Camandola S: Curcumin requires tumor necrosis factor alpha signaling to alleviate cognitive impairment elicited by lipopolysaccharide. Neurosignals 2013, 21:75-88.
36. Glezer I, Munhoz CD, Kawamoto EM, Marcourakis T, Avellar MC, Scavone C: MK-801 and 7-Ni attenuate the activation of brain NF-kappa B induced by LPS. Neuropharmacology 2003, 45:1120-1129.
37. Laflamme N, Rivest S: Effects of systemic immunogenic insults and circulating proinflammatory cytokines on the transcription of the inhibitory factor kappaB alpha within specific cellular populations of the rat brain. J Neurochem 1999, 73:309-321.
38. Munhoz CD, Lepsch LB, Kawamoto EM, Malta MB, Lima Lde S, Avellar MC, Sapolsky RM, Scavone C: Chronic unpredictable stress exacerbates lipopolysaccharide-induced activation of nuclear factor-kappaB in the frontal cortex and hippocampus via glucocorticoid secretion. J Neurosci 2006, 26:3813-3820.
39. Rong Y, Baudry M: Seizure activity results in a rapid induction of nuclear factor-kappa B in adult but not juvenile rat limbic structures. J Neurochem. 1996, 67:662-668.
40. Salinovich O, Montelaro R: Reversible staining and peptide mapping of protein transferred to nitrocellulose after separation by SDS-PAGE. Anal Biochem 1986, 156:341-347.
41. Esmann M: ATPase and phosphatase activity of Na+, K + -ATPase: molar and specific activity, protein determination. Methods Enzymol 1988, 156:105-115.
42. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254.
43. Gonzales-Scarano F, Baltuch G: Microglia as mediators of inflammatory and degenerative diseases. Annu Rev Neurosci 1999, 22:219-240.
44. Heese K, Fiebich B, Bauer J, Otten U: NF-kappaB modulates lipopolysaccharide-induced microglial nerve growth factor expression. Glia 1998, 22:401-407.
45. Markus RP, Cecon E, Pires-Lapa MA: Immune-pineal axis: nuclear factor κB (NF-kB) mediates the shift in the melatonin source from pinealocytes to immune competent cells. Int J Mol Sci 2013, 14:10979-10997.
46. Laflamme N, Soucy G, Rivest S: Circulating cell wall components derived from Gram-negative, not Gram-positive, bacteria cause a profound induction of the gene-encoding Toll-like receptor 2 in the CNS. J Neurochem 2001, 79:648-657.
47. Fu H, Yang T, Xiao W, Fan L, Wu Y, Terrando N, Wang T: Prolonged neuroinflammation after lipopolysaccharide exposure in aged rats. Plos One 2014, 9:e106331.
48. Monje M, Toda H, Palmer T: Inflammatory blockade restores adult hippocampal neurogenesis. Science 2003, 302:1760-1765.
49. Li J, Khodus GR, Kruusmagi M, Kamali-Zare P, Liu XL, Eklof AC, Zelenin S, Brismar H, Aperia A: Ouabain protects against adverse developmental programming of the kidney. Nat Commun 2010, 1:1-7.
50. Orlov SN, Taurin S, Hamet P: The alpha1-Na/K pump does not mediate the involvement of ouabain in the development of hypertension in rats. Blood Press 2002, 11:56-62.
51. Schoner W, Scheiner-Bobis G: Endogenous and exogenous cardiac glycosides: their roles in hypertension, salt metabolism, and cell growth. Am J Physiol Cell Physiol 2007, 293:C509-C536.
52. Cameron H, McKay R: Adult neurogenesis produces a large pool of new granule cells in the dentate gyrus. J Comp Neurol 2001, 435:406-417.
53. Kawamoto EM, Lima LS, Munhoz CD, Yshii LM, Kinoshita PF, Amara FG, Pestana RR, Orellana AM, Cipolla-Neto J, Britto LR, Avellar MC, Rossoni LV, Scavone C: Influence of N-methyl-D-aspartate receptors on ouabain activation of nuclear factor-kappaB in the rat hippocampus. J Neurosci Res 2012, 90:213-228.
54. de Sa LL, Kawamoto EM, Munhoz CD, Kinoshita PF, Orellana AM, Curi R, Rossoni LV, Avellar MC, Scavone C: Ouabain activates NFkappaB through an NMDA signaling pathway in cultured cerebellar cells. Neuropharmacology 2013, 73:327-336.
55. Rolls A, Shechter R, London A, Ziv Y, Ronen A, Levy R, Schwartz M: Toll-like receptors modulate adult hippocampal neurogenesis. Nat Cell Biol 2007, 9:1081-1088.
56. Chen A, Xiong L, Tong Y, Mao M: The neuroprotective roles of BDNF in hypoxic ischemic brain injury. Biomed Rep 2013, 1:167-176.
57. Valente RC, Capella LS, Monteiro RQ, Rumjanek VM, Lopes AG, Capella MA: Mechanisms of ouabain toxicity. FASEB J 2003, 17:1700-1702.
58. Orlov SN, Thorin-Trescases N, Pchejetski D, Taurin S, Farhat N, Tremblay J, Thorin E, Hamet P: Na/K pump and endothelial cell survival: [Na ]i/[K ]i-independent necrosis triggered by ouabain, and protection against apoptosis mediated by elevation of [Na]i. Pflugers Arch 2004, 448:335-345.
59. Li J, Zelenin S, Aperia A, Aizman O: Low doses of ouabain protect from serum deprivation-triggered apoptosis and stimulate kidney cell proliferation via activation of NF-kappaB. J Am Soc Nephrol 2006, 17:1848-1857.
60. Pasdois P, Quinlan CL, Rissa A, Tariosse L, Vinassa B, Costa AD, Pierre SV, Dos Santos P, Garlid KD: Ouabain protects rat hearts against ischemia-reperfusion injury via pathway involving src kinase, mitoKATP, and ROS. Am J Physiol Heart Circ Physiol 2007, 292:H1470-H1478.
61. Yang Q, Huang W, Jozwik C, Lin Y, Glasman M, Caohuy H, Srivastava M, Esposito D, Gillette W, Hartley J, Pollard HB: Cardiac glycosides inhibit TNF-alpha/NF-kappaB signaling by blocking recruitment of TNF receptor-associated death domain to the TNF receptor. Proc Natl Acad Sci U S A 2005, 102:9631-9636.
62. de Vasconcelos DI, Leite JA, Carneiro LT, Piuvezam MR, de Lima MR, de Morais LC, Rumjanek VM, Rodrigues-Mascarenhas S: Anti-inflammatory and antinociceptive activity of ouabain in mice. Mediators Inflamm 2011, 2011:912925.
63. Matsumori A, Ono K, Nishio R, Igata H, Shioi T, Matsui S, Furukawa Y, Iwasaki A, Nose Y, Sasayama S: Modulation of cytokine production and protection against lethal endotoxemia by the cardiac glycoside ouabain. Circulation 1997, 96:1501-1506.
64. Ye J, Chen S, Maniatis T: Cardiac glycosides are potent inhibitors of interferon-beta gene expression. Nat Chem Biol 2011, 7:25-33.
65. Forshammar J, Block L, Lundborg C, Biber B, Hansson E: Naloxone and ouabain in ultralow concentrations restore Na+/K + -ATPase and cytoskeleton in lipopolysaccharide-treated astrocytes. J Biol Chem 2011, 286:31586-31597.
66. Forshammar J, Jörneberg P, Björklund U, Westerlund A, Lundborg C, Biber B, Hansson E: Anti-inflammatory substances can influence some glial cell types but not others. Brain Res 2013, 1539:34-40.